|
1
|
Aggarwal R, Zhang T, Small EJ and
Armstrong AJ: Neuroendocrine prostate cancer: Subtypes, biology,
and clinical outcomes. J Natl Compr Canc Netw. 12:719–726.
2014.PubMed/NCBI
|
|
2
|
Wang HT, Yao YH, Li BG, Tang Y, Chang JW
and Zhang J: Neuroendocrine Prostate Cancer (NEPC) progressing from
conventional prostatic adenocarcinoma: Factors associated with time
to development of NEPC and survival from NEPC diagnosis - a
systematic review and pooled analysis. J Clin Oncol. 32:3383–3390.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Marcus DM, Goodman M, Jani AB, Osunkoya AO
and Rossi PJ: A comprehensive review of incidence and survival in
patients with rare histological variants of prostate cancer in the
United States from 1973 to 2008. Prostate Cancer Prostatic Dis.
15:283–288. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fléchon A, Pouessel D, Ferlay C, Perol D,
Beuzeboc P, Gravis G, Joly F, Oudard S, Deplanque G, Zanetta S, et
al: Phase II study of carboplatin and etoposide in patients with
anaplastic progressive metastatic castration-resistant prostate
cancer (mCRPC) with or without neuroendocrine differentiation:
Results of the French Genito-Urinary Tumor Group (GETUG) P01 trial.
Ann Oncol. 22:2476–2481. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fjällskog ML, Granberg DP, Welin SL,
Eriksson C, Oberg KE, Janson ET and Eriksson BK: Treatment with
cisplatin and etoposide in patients with neuroendocrine tumors.
Cancer. 92:1101–1107. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Palmgren JS, Karavadia SS and Wakefield
MR: Unusual and underappreciated: Small cell carcinoma of the
prostate. Semin Oncol. 34:22–29. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chung MS, Lee SH, Lee DH and Chung BH:
Evaluation of the 7th American Joint Committee on cancer TNM
staging system for prostate cancer in point of classification of
bladder neck invasion. Jpn J Clin Oncol. 43:184–188. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lipianskaya J, Cohen A, Chen CJ, Hsia E,
Squires J, Li Z, Zhang Y, Li W, Chen X, Xu H and Huang J:
Androgen-deprivation therapy-induced aggressive prostate cancer
with neuroendocrine differentiation. Asian J Androl. 16:541–544.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Beltran H, Tagawa ST, Park K, MacDonald T,
Milowsky MI, Mosquera JM, Rubin MA and Nanus DM: Challenges in
recognizing treatment-related neuroendocrine prostate cancer. J
Clin Oncol. 30:e386–e389. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Di Sant'Agnese PA and Cockett AT: The
prostatic endocrine-paracrine (neuroendocrine) regulatory system
and neuroendocrine differentiation in prostatic carcinoma: A review
and future directions in basic research. J Urol. 152:1927–1931.
1994.PubMed/NCBI
|
|
11
|
Ramírez-Balderrama L, López-Briones S,
Daza-Benítez L, Macías MH, López-Gaytán T and Pérez-Vázquez V:
Neuroendocrine differentiation in prostate adenocarcinoma. Gac Med
Mex. 149:639–645. 2013.(In Spanish). PubMed/NCBI
|
|
12
|
Kinebuchi Y, Noguchi W, Irie K, Nakayama
T, Kato H and Nishizawa O: Relapsed prostate cancer with
neuroendocrine differentiation and high serum levels of
carcinoembryonic antigen without elevation of prostrate-specific
antigen: A case report. Int J Urol. 14:147–149. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Epstein JI, Amin MB, Beltran H, Lotan TL,
Mosquera JM, Reuter VE, Robinson BD, Troncoso P and Rubin MA:
Proposed morphologic classification of prostate cancer with
neuroendocrine differentiation. Am J Surg Pathol. 38:756–767. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tanaka M, Suzuki Y, Takaoka K, Suzuki N,
Murakami S, Matsuzaki O and Shimazaki J: Progression of prostate
cancer to neuroendocrine cell tumor. Int J Urol. 8:431–437. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Marcus DM, Goodman M, Jani AB, Osunkoya AO
and Rossi PJ: A comprehensive review of incidence and survival in
patients with rare histological variants of prostate cancer in the
United States from 1973 to 2008. Prostate Cancer Prostatic Dis.
15:283–288. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yashi M, Terauchi F, Nukui A, Ochi M,
Yuzawa M, Hara Y and Morita T: Small-cell neuroendocrine carcinoma
as a variant form of prostate cancer recurrence: A case report and
short literature review. Urol Oncol. 24:313–317. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Reichardt P: Systematic hormone- and
chemotherapy in the management of skeletal metastases. Orthopade.
27:240–244. 1998.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lipianskaya J, Cohen A, Chen CJ, Hsia E,
Squires J, Li Z, Zhang Y, Li W, Chen X, Xu H and Huang J:
Androgen-deprivation therapy-induced aggressive prostate cancer
with neuroendocrine differentiation. Asian J Androl. 16:541–544.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Aragon-Ching JB: The evolution of prostate
cancer therapy: Targeting the androgen receptor. Front Oncol.
4:2952014. View Article : Google Scholar : PubMed/NCBI
|
